When diagnosing lung metastases and second primary lung cancer in patients with head and neck cancer, low-dose CT leads to better sensitivity than chest x-ray but does not lead to improved overall ...

The patient’s own doctors couldn’t agree on a cause. One said asthma. Another implicated her age, then 71. A third blamed ...

At-home cancer screening kits, particularly those for colon cancer, have gained traction in recent years. “To my knowledge, ...

In the continuing evolution of personalized medicine, a new study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with ...

Clinical stage diagnostics company AccuStem Sciences has acquired the licence for the microRNA Signature Classifier (MSC) ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

Researchers from Cambridge University have developed a first-of-its-kind test that can pick up “zombie cells”, linked to the ...

AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026LONDON and PHOENIX, Ariz., March 18, 2025 ...

Feb. 25, 2025 — Our organs age at different rates, and a blood test determining how much they've each aged could predict the risk of conditions like lung cancer and heart disease decades later ...

The firm is preparing for a trial to show the efficacy of its CyPath Lung test and support a submission to the US Food and Drug Administration for marketing clearance.